查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1698491

口服给药市场：未来预测（2025-2030）

Oral Drug Delivery Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 151 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

口服给药市场预计将从 2025 年的 1,339.44 亿美元成长到 2030 年的 1,695.86 亿美元，复合年增长率为 4.83%。

口服给药被认为是最常见的给药方法，因为它是非侵入性的，患者遵从率高，易于操作，不需要特殊的无菌条件。因此受到广大患者的欢迎。由于世界各地慢性病的流行，这种药物输送方法的需求量很大。此外，研发投资的增加、医疗保健支出的增加以及人口老化可能会促进整个预测期内的市场扩张。

市场趋势：

  • 慢性病流行：全球慢性病的快速增加，对口服给药市场的扩张起了很大的推动作用。此方法为心血管疾病、癌症、糖尿病等患者提供了一种无痛、便捷的给药方式。另一个好处是它减少了监测的需要并降低了医疗成本。尤其是全球糖尿病的盛行率正在急剧上升，英国糖尿病协会报告称，预计2022-23年间，光是英国就将出现440万例糖尿病病例，这凸显了对有效口服给药解决方案的需求日益增长。
  • 增加研发投资：药物输送技术的进步加上製药业活性化的研发投资是市场成长的关键驱动力。
  • 北美市场的主导地位：由于技术创新、专利审批的增加以及奈米技术在药物传输应用方面的开创性研究，北美有望占据口服药物传输市场的很大一部分。特别是，美国预计将占据相当大的市场占有率，因为它是尖端药物输送技术的早期采用者，并且在整个预测期内其研究中心都致力于开发新的口服药物输送系统。

报告中介绍的主要企业包括辉瑞、Astra Zeneca、Alpex Pharma SA、SPI Pharma、Globela Pharma Pvt Ltd.、Lupin Pharmaceuticals, Inc.、Mayne Pharma Group Limited、Adare Pharmaceuticals, Inc.、AdhexPharma、Aquestive Therapeutics、RAUMEDIC 和 Croda International Plc。

本报告的主要优点

  • 深刻分析：获得涵盖主要地区和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业采取的策略策略，并了解正确策略带来的潜在市场渗透。
  • 市场驱动因素和未来趋势：探索动态因素和关键市场趋势以及它们将如何影响市场的未来发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 适用范围广：对于新兴企业、研究机构、顾问公司、中小企业和大型企业来说，它都是实用且具有成本效益的。

它有什么用途？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

分析范围

  • 历史资料（2022-2024）和预测资料（2025-2030）
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按部门和地区（国家）分類的收益成长和预测分析
  • 公司概况（策略、产品、财务资讯、主要趋势等）

口服给药市场细分：

按剂型

  • 锭剂
  • 胶囊
  • 降低
  • 粉末
  • 液体/糖浆
  • 汤

按应用

  • 疾病治疗
  • 研究和学术目的

按地区

  • 北美洲
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东和非洲

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业景气

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

第五章 口服给药市场（以剂型）

  • 介绍
  • 锭剂
  • 胶囊
  • 降低
  • 粉末
  • 液体/糖浆
  • 汤

第六章口服给药市场（依应用）

  • 介绍
  • 疾病治疗
  • 研究和学术目的

7. 口服给药市场（按地区）

  • 介绍
  • 北美洲
    • 按剂型
    • 按应用
    • 按国家
  • 南美洲
    • 按剂型
    • 按应用
    • 按国家
  • 欧洲
    • 按剂型
    • 按应用
    • 按国家
  • 中东和非洲
    • 按剂型
    • 按应用
    • 按国家
  • 亚太地区
    • 按剂型
    • 按应用
    • 按国家

第八章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 企业合併、协议、商业合作
  • 竞争仪錶板

第九章 公司简介

  • Pfizer Inc.
  • AstraZeneca
  • Alpex Pharma SA
  • SPI Pharma
  • Globela Pharma Pvt Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Mayne Pharma Group Limited
  • Adare Pharmaceuticals, Inc.
  • AdhexPharma
  • Aquestive Therapeutics
  • RAUMEDIC
  • Croda International Plc

第十章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061612656

The oral drug delivery market is forecasted to attain US$169.586 billion in 2030 at a CAGR of 4.83%, rising from US$133.944 billion in 2025.

Oral drug delivery is non-invasive, has a high rate of patient compliance, is easy to handle, and does not require any special sterile conditions; it is considered the most popular method of administration. Hence, it is highly preferred by a wide spectrum of patients. This drug delivery method is in high demand because of the prevalence of chronic diseases worldwide. Moreover, rising research and development investment, advancing health expenditure, and an aging population will all contribute to market expansion throughout the projection period.

Market Trends:

  • Rise in Chronic Disease Prevalence: The global surge in chronic illnesses significantly contributes to the expansion of the oral drug delivery market. This method provides a painless and convenient option for administering medication to patients with conditions such as cardiovascular diseases, cancer, and diabetes. It also benefits from reduced oversight requirements and lower care costs. Notably, the prevalence of diabetes has spiked globally, with Diabetes UK reporting a total of 4.4 million cases in the UK alone during 2022-23, underscoring the growing demand for effective oral drug delivery solutions.
  • Increased Investment in Research and Development: Advancements in drug delivery technologies, coupled with heightened R&D investments within the pharmaceutical industry, are pivotal in driving market growth.
  • North America's Market Dominance: North America is poised to capture a substantial portion of the oral drug delivery market, fueled by technological innovations, an increase in patent approvals, and pioneering research into nanotechnology applications for drug delivery. The United States, in particular, is anticipated to command a significant market share, thanks to its quick uptake of cutting-edge drug delivery technologies and the presence of research hubs focused on developing novel oral drug delivery systems throughout the forecast period.

Some of the major players covered in this report include Pfizer Inc., AstraZeneca, Alpex Pharma S.A., SPI Pharma, Globela Pharma Pvt Ltd., Lupin Pharmaceuticals, Inc., Mayne Pharma Group Limited, Adare Pharmaceuticals, Inc., AdhexPharma, Aquestive Therapeutics, RAUMEDIC, and Croda International Plc, among others.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Oral Drug Delivery Market Segmentation:

By Formulation

  • Tablets
  • Capsules
  • Drops
  • Powder
  • Liquid or Syrup
  • Decoction

By Application

  • Disease Treatment
  • Research/Academic purposes

By Region

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ORAL DRUG DELIVERY MARKET BY FORMULATION

  • 5.1. Introduction
  • 5.2. Tablets
  • 5.3. Capsules
  • 5.4. Drops
  • 5.5. Powder
  • 5.6. Liquid or Syrup
  • 5.7. Decoction

6. ORAL DRUG DELIVERY MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Disease Treatment
  • 6.3. Research/Academic purposes

7. ORAL DRUG DELIVERY MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Formulation
    • 7.2.2. By Application
    • 7.2.3. By Country
      • 7.2.3.1. USA
      • 7.2.3.2. Canada
      • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Formulation
    • 7.3.2. By Application
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
      • 7.3.3.2. Argentina
      • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Formulation
    • 7.4.2. By Application
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
      • 7.4.3.2. Germany
      • 7.4.3.3. France
      • 7.4.3.4. Spain
      • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Formulation
    • 7.5.2. By Application
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
      • 7.5.3.2. UAE
      • 7.5.3.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Formulation
    • 7.6.2. By Application
    • 7.6.3. By Country
      • 7.6.3.1. China
      • 7.6.3.2. Japan
      • 7.6.3.3. India
      • 7.6.3.4. South Korea
      • 7.6.3.5. Taiwan
      • 7.6.3.6. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Pfizer Inc.
  • 9.2. AstraZeneca
  • 9.3. Alpex Pharma S.A.
  • 9.4. SPI Pharma
  • 9.5. Globela Pharma Pvt Ltd.
  • 9.6. Lupin Pharmaceuticals, Inc.
  • 9.7. Mayne Pharma Group Limited
  • 9.8. Adare Pharmaceuticals, Inc.
  • 9.9. AdhexPharma
  • 9.10. Aquestive Therapeutics
  • 9.11. RAUMEDIC
  • 9.12. Croda International Plc

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key benefits for the stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations